Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

被引：2

作者：

Davies, Andrew J. ^{[1
,2
]}

Caddy, Josh ^{[3
]}

McLaughlin, Katy ^{[3
]}

Wignall, Christopher ^{[3
]}

Waugh, Robert ^{[3
]}

Collins, Graham P. ^{[4
]}

Stanton, Louise ^{[3
]}

Saunders, Geoff N. ^{[3
]}

Cummin, Thomas ^{[5
]}

Schuh, Anna ^{[6
]}

Ardeshna, Kirit M. ^{[7
]}

McMillan, Andrew K. ^{[8
]}

Radford, John ^{[9
,10
]}

Lewis, David John ^{[11
]}

Coleman, Adam R. ^{[1
]}

Griffiths, Gareth ^{[3
]}

Burton, Cathy ^{[12
]}

Barrans, Sharon ^{[12
]}

Johnson, Peter ^{[1
,13
]}

机构：

[1] Canc Res UK Expt Canc Med Ctr UK, Southampton, Hants, England

[2] Southampton Canc Res UK Ctr, Southampton, Hants, England

[3] Univ Southampton, Canc Res UK Southampton Clin Trials Unit, Southampton, Hants, England

[4] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England

[5] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[6] Univ Oxford, Oxford Mol Diagnost Ctr, Oxford, England

[7] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England

[8] Nottingham Univ Hosp NHS Trust, Nottingham, England

[9] Univ Manchester, NIHR Clin Res Facil, Manchester, Lancs, England

[10] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England

[11] Derriford Hosp, Dept Haematol, Plymouth, Devon, England

[12] Leeds Canc Ctr, Haematol Malignancy Diagnost Serv, Leeds, W Yorkshire, England

[13] Univ Southampton, Fac Med, Sch Canc Sci, Southampton, Hants, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163499

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9478 / 9479

页数：2

共 50 条

[1] Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
Davies, Andrew
Caddy, Josh
Mercer, Katy
Saunders, Geoff N.
Stanton, Louise
Collins, Graham P.
Cummin, Thomas E. C.
Schuh, Anna
Ardeshna, Kirit M.
McMillan, Andrew
Radford, John A.
Lewis, David John
Coleman, Adam
Griffiths, Gareth
Burton, Cathy
Barrans, Sharon
Johnson, Peter
BLOOD, 2020, 136
[2] ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
Johnson, Peter W. M.
Caddy, Joshua
Cumin, Tom
Merton, Bridgen
Maishman, Tom
Galanopoulou, Angelic
Griffiths, Gareth
Davies, Andrew
CANCER RESEARCH, 2018, 78 (13)
[3] Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma
Candelaria, Myrna
Duenas-Gonzalez, Alfonso
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
[4] OUTCOMES IN PATIENTS WITH PRIMARY GASTRIC DIFFUSE LARGE B-CELL LYMPHOMA AFTER RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISOLONE (R-CHOP) CHEMOTHERAPY
Suh, C.
Sohn, B. S.
Yoon, D. H.
Kim, S.
Lee, D. H.
Kim, S. W.
Huh, J. R.
Lee, J. S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 650 - 650
[5] Outcomes in patients with primary gastric diffuse large B-cell lymphoma after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy
Sohn, B.
Yoon, D.
Kim, S.
Lee, D.
Kim, S.
Huh, J.
Lee, J.
Suh, C.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[6] Pharmacokinetic and pharmacodynamic evaluation of a biosimilar rituximab in newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone)
Viswabandya, Auto
Prashanthi, P. V.
Raju, C. Nirmala
Rajsekhar, Reena
Mathews, Vikram
Madki, Shivkumar
Abhayankar, Dhiraj
Kethireddypally, Rukmini
George, Biju
Chandy, Mammen
Reddy, Cartikeya
Srivastava, Alok
BLOOD, 2007, 110 (11) : 194B - 194B
[7] Zanubrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results from a Phase 1b Clinical Trial
Sawalha, Yazeed
Welkie, Rina Li
Krivenko, Anna
Hess, Brian
Sigmund, Audrey M.
Voorhees, Timothy
Hanel, Walter
Bond, David A.
Reneau, John C.
Epperla, Narendranath
Alinari, Lapo
Brammer, Jonathan E.
Christian, Beth
Baiocchi, Robert
Maddocks, Kami J.
BLOOD, 2023, 142
[8] Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
Morschhauser, Franck
Feugier, Pierre
Flinn, Ian W.
Gasiorowski, Robin E.
Greil, Richard
Illes, Arpad
Johnson, Nathalie A.
Larouche, Jean-Francois
Lugtenburg, Pieternella J.
Patti, Caterina
Salles, Gilles
Trneny, Marek
de Vos, Sven
Mir, Farheen
Kornacker, Martin
Punnoose, Elizabeth A.
Samineni, Divya
Szafer-Glusman, Edith
Petrich, Adam
Sinha, Arijit
Mobasher, Mehrdad
Zelenetz, Andrew D.
BLOOD, 2018, 132
[9] Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma
Wöhrer, S
Püspök, A
Drach, J
Hejna, M
Chott, A
Raderer, M
ANNALS OF ONCOLOGY, 2004, 15 (07) : 1086 - 1090
[10] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
Dietrich, Sascha
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, Marek
Sharman, Jeff
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yu Qin
Greil, Richard
Mykhalska, Larysa
Bergua Burgues, Juan Miguel
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Salles, Gilles
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165

← 1 2 3 4 5 →